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Abstract
Background: There is an urgent need to improve the evidence base for provision of second-line antiretroviral therapy (ART)
following first-line virological failure. This is particularly the case in Sub-Saharan Africa where 70% of all people living with
HIV/AIDS (PHA) reside. The aim of this study was to simulate the potential risks and benefits of treatment simplification in
second-line therapy compared to the current standard of care (SOC) in a lower-middle income and an upper-middle income
country in Sub-Saharan Africa.
Methods: We developed a microsimulation model to compare outcomes associated with reducing treatment
discontinuations between current SOC for second-line therapy in South Africa and Nigeria and an alternative regimen:
ritonavir-boosted lopinavir (LPV/r) combined with raltegravir (RAL). We used published studies and collaborating sites to
estimate efficacy, adverse effect and cost. Model outcomes were reported as incremental cost effectiveness ratios (ICERs) in
2011 USD per quality adjusted life year ($/QALY) gained.
Results: Reducing treatment discontinuations with LPV/r+RAL resulted in an additional 0.4 discounted QALYs and increased
the undiscounted life expectancy by 0.8 years per person compared to the current SOC. The average incremental cost was
$6,525 per treated patient in Nigeria and $4,409 per treated patient in South Africa. The cost-effectiveness ratios were
$16,302/QALY gained and $11,085/QALY gained for Nigeria and South Africa, respectively. Our results were sensitive to the
probability of ART discontinuation and the unit cost for RAL.
Conclusions: The combination of raltegravir and ritonavir-boosted lopinavir was projected to be cost-effective in South
Africa. However, at its current price, it is unlikely to be cost-effective in Nigeria.
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Introduction
In June 2001 the United Nations issued a Declaration of
Commitment to facilitate and support a global effort to combat the
HIV/AIDS pandemic through a combination of prevention and
treatment initiatives made universally available to all people living
with HIV/AIDS (PHA). UNAIDS recently reported that since this
initiative began there are encouraging signs of success, including
evidence of an absolute reduction in new HIV infections [1].
UNAIDS reported that more than 6.5 million people (of a UN
agreed target of 15 million by 2015) had access to combination
antiretroviral therapy (ART) by the end of 2010 [1]. The majority
of these individuals are receiving standard first-line ART
combinations comprising of one drug selected from the non-
nucleoside reverse transcriptase inhibitor (NNRTI) class with two
drugs from the nucleoside/nucleotide reverse transcriptase inhib-
itor (N(t)RTI) class. While this approach is recommended for the
initiation of ART, there is inevitable attrition. HIV ultimately
develops resistance, resulting in virological failure and HIV disease
progression [2]. An analysis in 2008 estimated that by 2010
between 500,000 and 800,000 people receiving first-line cART
would have qualified for a switch to second-line therapy, causing
the cost of second-line therapy to increase from 2% in 2006 to
35% in 2010 of the total cost [3]. Unfortunately, there is no
evidence to guide how treatment of these people should be
managed. The challenge of this un-met clinical need grows daily.
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The current standard of care (SOC) for second-line ART
consists of the introduction of a new class of ART, a ritonavir-
boosted protease inhibitor, combined with two N(t)RTIs. This
strategy is generally successful in settings in which virological
monitoring is done 3–4 monthly, thereby minimising the selection
of resistance in those considered to have virologically failed first-
line ART [4]. However, in resource-limited settings most patients
are managed in the absence of virological monitoring using clinical
and/or immunological measures. These are neither sensitive nor
specific for virological failure. As a result, when failure is detected
most patients have substantial degrees of resistance to both the
NNRTI and NRTI ART classes [5–7]. Use of agents from the
N(t)RTI class in this context may contribute little to efficacy but
substantially to intolerability and toxicity, particularly given their
routine use in first-line ART.
Two research institutions are currently sponsoring the conduct
of two independent randomised controlled trials (RCT). These
both attempt to provide a firmer evidence base for guidelines for
the provision of second-line ART after the failure of first-line. The
Kirby Institute is conducting a non-inferiority design RCT
(SECOND-LINE; NCT00931463) to compare the use of a SOC
second line combination ART of ritonavir-boosted lopinavir
(LPV/r) with 223 N(t)RTIs versus a novel nuke-sparing
combination of LPV/r combined with raltegravir (RAL), the
first-in-class HIV integrase strand transfer inhibitor (InSTI). The
UK Medical Research Council is sponsoring the conduct of the
EARNEST RCT (NCT00988039) which asks a similar question
with the same agents but with a third comparator that employs
LPV/r monotherapy front-end loaded with RAL for a fixed period
of the first 12 weeks. Both RCTs test whether the novel
combination of a boosted-PI plus RAL provides non-inferior
efficacy to SOC. They also test whether it is more tolerable and
less toxic using safety endpoints within the parent study as well as
nested dual energy X-ray absorptiometry (DXA) sub-studies. If
successful, the experimental arms (either LPV/r plus RAL or
LPV/r monotherapy with front-end loaded RAL) would not
require implementation of resistance testing to select second-line
therapy because resistance selected in first-line would be imma-
terial to treatment outcomes of second-line ART.
The use of raltegravir in combination ART has been associated
with less drug-related toxicity and adverse events when compared
with other drug combinations currently available. It has a benign
metabolic profile superior to that conferred by most other ART
[8,9]. However, regimens that include raltegravir are 6 to almost
20 times more expensive than the cost of the current first and
second-line ARTs for Sub-Saharan Africa [10]. They are therefore
thought to be priced out of reach for this setting. Raltegravir is
currently not recommended for second-line therapy in national
guidelines in Sub-Saharan Africa and is not routinely supplied or
available from international groups supporting universal access to
care in low and middle-income settings such as PEPFAR.
Nevertheless, increased cost does not necessarily equate with
diminished cost-effectiveness, particularly if the agent is associated
with tangible benefits which may contribute to improved
productivity and quality of life. While there are currently no
published results of trials investigating LPV/r+RAL and LPV/
r+2-3N(t)RTIs as a second-line therapy, we estimate the cost and
likely consequences of treatment simplification with LPV/r+RAL
compared to the standard of care (SOC) from published studies
and collaborating sites. This methodology was inspired by a
previously published simulation model projecting the long-term
outcomes of treatment simplification to inform the design of a
multicentre, randomised clinical trial [11]. We undertook a cost-
effectiveness analysis of the application of the experimental
regimen for two settings in Sub-Saharan Africa in which the
RCT is itself being conducted – Nigeria (a lower-middle income
country) and South Africa (an upper-middle income country).
The aim of this study was to simulate the potential risks and
benefits of a novel simplification treatment strategy for second-line
therapy, including cost-effectiveness, in order to help understand
likely determinants of value. The results were used to calculate the
incremental cost-effectiveness ratio (ICER) as the incremental cost
per quality adjusted life years ($/QALY) gained from using LPV/r
+ RAL compared with LPV/r+2-3N(t)RTIs.
Methodology
We developed a computer-based microsimulation model of
HIV disease to evaluate the long-term outcomes for patients
experiencing treatment failure of first-line ART (NNRTI
+2N(t)RTIs) assigned to receive either LPV/r+RAL or LPV/
r+2-3N(t)RTIs. We used decision analysis software (TreeAge Pro
2012; TreeAge Software, Boston, MA) to develop and analyse the
model and perform sensitivity analyses using a 50 year time
horizon from the perspective of the health-care provider. The
economic model was built to simulate the likely disease progression
of HIV-infected patients that were N(t)RTI and NNRTI
experienced with treatment failure and unsuppressed HIV
replication. Patients in the model were stratified according to
CD4+ T-cell count, viral failure and adverse event history. Patients
could transition into different health states over time based on
projected long-term treatment efficacy. Weekly probabilities of
clinical events including treatment failure, changes in the CD4+ T-
cell count, adverse reactions to medications and death were used
to simulate the course of disease in a hypothetical cohort of HIV-
infected persons. Each state was associated with a specific
treatment cost and quality of life utility. Costs and consequences
were further investigated in deterministic and probabilistic
sensitivity analyses. Incremental cost effectiveness ratios were
expressed as 2011 US dollars per quality-adjusted life year ($/
QALY) gained.
The model
The model used in this study was based on a 16-compartment
Markov model (Figure 1). Expected mean values for the base case
analysis were estimated by sampling from a distribution of paths
through the model’s chance events in 10,000 first-order simulation
trials (microsimulation). Individuals were assumed to enter the
model with unsuppressed viremia and were distributed across the
four possible CD4+ T-cell count compartments, skewed toward
fewer CD4+ T-cells: 5%: CD4+$500, 10%: 350#CD4+,500,
30%: 200#CD4+,350, 55%: CD4+,200) (Figure 1). This
stratification was chosen to reflect a cohort of individuals who
have failed first-line therapy by clinical and/or immunological
means and who are therefore relatively immunodeficient [12].
During each weekly cycle, individuals in the model faced a
series of different chance events that were dependent on the health
state in which they started the cycle. Firstly, there is a probability
that treatment leads to suppression of virus replication, char-
acterised by increased CD4+ T-cell count. There are likewise a
proportion of individuals who do not achieve suppression and
move to health states characterised by losses of CD4+ T-cells.
These people are representative of people who either have
problems adhering adequately to ART or have developed drug
resistance [13]. While an individual in the model remains on
treatment they have a probability of experiencing a drug-related
adverse event and a proportion will discontinue treatment as a
consequence. A treated individual in the model also has a
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probability of confirmed viral rebound, at which point it is
assumed that CD4+ T-cell count will decline. Individuals who have
failed treatment virologically are assumed to remain on ART until
they become immunodeficient and experience declines in CD4+
T-cells to below 200 cell/mL. We assume no additional treatment
is supplied in the model after second-line therapy.
Treatment efficacy in our model was based on a recently
published meta-analysis reporting on the rate of treatment failure
among people on second-line therapy in resource-limited settings
[13] (Table 1). While a SOC second-line regimen was the
preferred treatment option for most studies in the analysis, we
assume the treatment efficacy of LPV/r+RAL to be non-inferior
to LPV/r+2-3N(t)RTIs. Therefore, the same treatment failure
rates are applied to both treatment arms in the model [13]. A
difference between the treatment arms was generated through the
rate of drug-related adverse events and the rate of treatment
discontinuation due to adverse events. For both treatment
strategies, these were estimated from the BENCHMRK trials
[14] (Table 1). These toxicity data were sourced for the base case
analyses because the patient population is most representative of
those initiating second-line therapy in resource-limited settings
compared with other clinical trials and observational studies to
date. However, these toxicity data are extensively analysed in
sensitivity analyses (Supporting Material S3).
Costing approach
All costs are expressed as 2011 US dollars and were discounted
at 3% per year for our base case scenario. We use a discount rate
of 0–5% in our sensitivity analyses (Supporting Material S3).
Healthcare costs were calculated using an ingredients approach
where the direct medical costs of ART, opportunistic infection
prophylaxis and other health resource utilisation (testing, moni-
toring, hospitalisation and clinic visits) are summed together to
estimate the overall cost (Supporting Material S2) [15,16]. All costs
are taken from the perspective of the health-care provider.
We assume the costs of LPV/r 200/50 mg + tenofovir
disoproxil fumarate and emtricitabine (TDF/FTC) 300/200 mg
for the SOC in both South Africa and Nigeria. We reference
Médecins Sans Frontières [10] for antiretroviral therapy costs for
the Nigerian setting and the 2011 recommended retail prices for
South Africa. Raltegravir is however not available in the open
market in Nigeria; we estimate Raltegravir to cost $95/month.
This cost represents the cost quoted by drug representatives when
clinicians negotiate to have the drug brought in by the company.
Quality-of-life
Quality of life utilities ranging between 1 (best possible health)
and 0 (death) were assigned to each health state in the model and
were informed by published data in the literature [17–21]. The
health states ‘‘CD4+$500’’ and ‘‘350#CD4+,500’’ were mapped
to utilities for asymptomatic infection, ‘‘200#CD4+,350’’ to
symptomatic infection, and ‘‘CD4+,200’’ to AIDS. Due to the
large variations in estimates of utility scores, a sensitivity analysis
was performed. Our base case estimates arise from a published
meta-analysis of utility estimates for HIV/AIDS [17]. Quality
adjusted life years were discounted at 3% per year for our base
case scenario.
Sensitivity analysis
Expected mean values were estimated by sampling from a
distribution of paths through the model’s chance events in 10,000
first-order simulation trials (microsimulation). We also performed
probabilistic sensitivity analyses (PSA) and deterministic sensitivity
analyses to examine the impact that uncertain parameters in the
model had on the ICER. We conducted PSA using second-order
Monte-Carlo simulations [22]. Second-order simulations capture
parameter uncertainty by running a one-dimensional loop that
recalculates expected values for each set of randomly sampled
parameter values. After a set of simulations are run, the overall
uncertainty in the model is captured by the confidence intervals
around each outcome. Simulations were run over 3,000 parameter
distribution values in our analysis.
Results
Nigeria
In the base case analysis, the reduction in treatment discontin-
uations estimated with LPV/r+RAL increased the undiscounted
life expectancy by 0.79 years and the discounted quality-adjusted
life years by 0.4 for an incremental cost of approximately $6,525
USD per person compared with the standard of care. The
resulting ICER was found to be $16,302 USD per discounted
quality adjusted life year gained and $10,335 USD per
undiscounted life year gained (Table 2). We assume the Nigerian
willingness-to-pay for an additional quality-adjusted life year is
Figure 1. Schematic diagram of transitions through the health states in the model.
doi:10.1371/journal.pone.0054435.g001
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approximately $7,800; this cost-effectiveness threshold represents
the 2011 GDP per capita of Nigeria (CIA World Factbook
estimate in US dollars calculated using purchasing power parities)
multiplied by three [23]. While assuming this to be the willingness-
to-pay threshold, LPV/r+RAL would not be considered cost-
effective for this setting.
Across 3,000 PSA iterations LPV/r+RAL was more effective
99.1% of the time and more costly in all iterations. The ICER
remained above the willingness-to-pay threshold in 99.97% of the
iterations (Figure 2A). The mean ICER for all 3,000 iterations was
found to be $18,818/QALY.
Table 1. Model transitions, and quality of life estimates.
Variable




Probability of death (HIV and non-HIV related) per year
CD4+$350 0.007 (0.00620.008) Triangular [29]
200#CD4+,350 0.014 (0.01120.017)
CD4+,200 0.083 (0.03320.406)
Treatment efficacy: viral suppression
Probability of viral suppression during first year on treatment 0.769 (0.7020.839) Triangular [13]
Probability of confirmed viral rebound during second year
on treatment
0.0467 Constant
Probability of confirmed viral rebound after second year
on treatment
0.155 Constant
Estimated probability of a drug related adverse event per yeara
LPV/r+2-3N(t)RTIs 0.40 (0.3620.44) Triangular [14]
LPV/r+RAL 0.28 (0.2520.31) Triangular
Estimated probability of discontinuing ART due to an adverse event per yearb
LPV/r+2-3N(t)RTIs 0.044 (0.0420.048) Triangular [14]
LPV/r+RAL 0.021 (0.01920.023) Triangular
CD4+ T-cell count increase with viral suppression while on ART (baseline CD4+,200) (years)
Increase from CD4+,200 to 200#CD4+,350 2.80 (2.3323.58) Triangular [30] c
Increase from 200#CD4+,350 to 350#CD4+,500 3.33 (2.1525.83)
Increase from 350#CD4+,500 to CD4+$500 4.69 (3.2628.33)
CD4+ T-cell count increase with viral suppression while on ART (baseline 200#CD4+,350) (years)
Increase from 200#CD4+,350 to 350#CD4+,500 1.42 (0.923.38) Triangular [30] c
Increase from 350#CD4+,500 to CD4+$500 3.11 (2.06234.83)
CD4+ T-cell count increase with viral suppression while on ART (baseline 350#CD4,500) (years)
Increase from 350#CD4+,500 to CD4+$500 2.2 (1.0727.28) Triangular [30] c
CD4+ T-cell count reduction with viral failure while on ART (years)
Drop from CD4+$500 to 350#CD4+,500 3.2 (1.1, 5.3#) Triangular [31] d
Drop from 350#CD4+,500 to 200#CD4+,350 2.1 (0.7, 3.5#)
Drop from 200#CD4+,350 to CD4+,200 2.2 (0.7, 3.7#)
CD4+ T-cell count reduction (not on ART) (years)
Drop from CD4+$500 to 350#CD4+,500 3.27 (3.02, 3.55) Triangular [32] e
Drop from 350#CD4+,500 to 200#CD4+,350 1.96 (1.81, 2.13)
Drop from 200#CD4+,350 to CD4+,200 1.96 (1.81, 2.13)
Quality of life estimates




a: The rates sourced from Steigbigel et al (2009) were transformed into probabilities using the Treeage RateToProb(rate; time) function. This function multiplies a rate by
time, and converts it into a probability. Calculations were as follows: ratetoprob (32.8;1/100) = 0.27963698, and ratetoprob (51.6;1/100) = 0.403096607.
b: Calculations were as follows: ratetoprob (2.1;1/100) = 0.020781035, and ratetoprob (4.5;1/100) = 0.044002518.
c,d,e: Supporting Material S1.
#: Upper bound assumption.
doi:10.1371/journal.pone.0054435.t001
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South Africa
Access to medical care in South Africa was found to be more
extensive and therefore more costly compared with Nigeria,
reducing the incremental cost between SOC and LPV/r+RAL
and therefore the ICER. The ICER was $11,085 USD per
discounted quality adjusted life year gained and $7,554 per
undiscounted life year gained (Table 2). We assume the South
African willingness-to-pay for an additional quality-adjusted life
year is $33,000. This estimated cost-effectiveness threshold
represents the 2011 GDP per capita of the South Africa (CIA
World Factbook estimate in US dollars calculated using purchas-
ing power parities) multiplied by three. While assuming this to be
the willingness-to-pay threshold, LPV/r+RAL would be consid-
ered to be cost-effective for this setting.
Across 3,000 PSA iterations conducted for the South African
setting, LPV/r+RAL was more effective 99.4% of the time. LPV/
r+RAL was found to be more costly in all iterations. The ICER
remained lower than the willingness-to-pay threshold 93.4% of the
time (Figure 2B). The mean ICER for all 3,000 iterations was
$13,313/QALY.
Deterministic sensitivity analyses
We conducted a series of one-way sensitivity analyses (Support-
ing Material S3). We found the ICER to be most sensitive to the
probability of ART discontinuation and the cost of RAL. The cost
of RAL in Nigeria was estimated in our base case analysis as
$21.92 USD per week per person. As shown in Figure 3A, RAL is
as cost-effective as SOC in Nigeria when $11.07 USD per week
per person. This corresponds to an annual cost of approximately
$576 USD. The price of RAL in South Africa was estimated to be
$21.86 USD per week per person. As shown in Figure 3B, this
price produced a higher net monetary benefit than SOC.
The WHO-preferred boosted protease inhibitors in the current
guidelines are LPV/r and atazanavir/r (ATV/r). The combina-
tion of ATV/r is generally 25% cheaper than LPV/r. We
therefore conducted a one-way sensitivity analysis on the cost of
the boosted-PI used in the model. It was found to have no effect on
the outcome of the model and only marginally reduced the overall
cost (Supporting Material S3).
Model validation
The projected outcomes produced by the model remained
within the range of values reported in the literature. We compared
the predicted mortality in our model with the reported mortality
on second-line ART in resource-limited settings from the Ajose
et al (2012) systematic review and meta-analysis [13]. Overall the
unpooled discrete rates of mortality on second-line was reported to
be low across all time points, 2.0–6.0% at 3 months, 5.0–10.0% at
12 months, and 5.0–7.0% at 24 months. Our model predicted a
base case mortality of 3.0% at 6 months, 7.0% at 12 months,
8.0% at 24 months and 97% after 50 years.
Discussion
This cost-effectiveness analysis predicts that a nuke-sparing
combination of LPV/r+RAL is likely to be cost-effective for upper
middle-income countries such as South Africa. In South Africa,
the benefit associated with fewer patients discontinuing treatment,
Table 2. Incremental cost-effectiveness of LPV/r+RAL vs. standard of care.
Strategy
Discounted total








Standard of care $9,322 9.58 17.12 $973 $16,302
Raltegravir $15,847 9.98 17.91 $1,588
South Africa
Standard of care $19,984 9.56 17.19 $2,090 $11,085
Raltegravir $24,393 9.96 17.98 $2,449
doi:10.1371/journal.pone.0054435.t002
Figure 2. Incremental cost-effectiveness scatter plots. A. Nigerian setting. B. South African setting.
doi:10.1371/journal.pone.0054435.g002
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fewer patients experiencing adverse events and fewer patients
experiencing HIV-disease progression events offset the increased
investment in RAL. However, in Nigeria there are fewer resources
for monitoring and medical care for each individual with HIV,
and the resources required to provide sufficient treatment and care
for PHA in Nigeria remain undersupplied. As a result there are
less costly consequences for patients who are sick, making the
introduction of a more costly and less toxic drug such as RAL not
cost-effective.
Our analysis has a number of limitations. First and foremost,
there are currently no published studies directly investigating
whether there is a clinical difference between LPV/r+RAL and
LPV/r+2-3N(t)RTIs among NRTI and NNRTI experienced
patients. In our analysis, we assume non-inferiority. Studies to
date have had mixed results. A small, single cohort study [24]
conducted in HIV-infected but ART-naive participants yielded
results that suggested that the combination of ritonavir-boosted
darunavir and RAL may be inferior to standard first-line ART
[24]. However, the PROGRESS randomised controlled trial
comparing the combination of LPV/r+RAL with LPV/r+TDF/
FTC suggested that the nuke-sparing drug combination offered
non-inferior efficacy, safety and tolerability compared to the
standard of care [25]. In addition, a DXA substudy of
PROGRESS suggests a clinically relevant soft-tissue and bone
toxicity advantage for the N(t)RTI-sparing strategy [26]. While no
study has published clinically significant differences between drug-
related adverse events, the rates of events among patients in the
BENCHMRK trials are markedly different, and are what we use
in our model [14].
A second limitation is the accuracy of our costing analysis.
There is little data currently available reporting on the cost and
utilisation of medical treatment for PHA in Sub-Saharan Africa.
We therefore had unit costs and utilisation of healthcare estimated
by physicians and other healthcare workers by an informal chart
review in collaborating clinical sites in Nigeria. For the South
African setting, unit costs were estimated from the National Health
Laboratory Service and the Bio Analytical Research Corporation
South Africa. Healthcare utilisation was estimated from data
published in the literature [27,28]. It is however unlikely that these
estimates are far from the true cost since they represent current
practice experience in the respective settings.
In conclusion, the combination of raltegravir and ritonavir-
boosted lopinavir was projected to be cost-effective for an upper-
middle income country in Sub-Saharan Africa. At its current
price, it is unlikely to be cost-effective for lower middle-income
countries such as Nigeria. However, with the additional presen-
tation of clinical results for RAL as a second-line therapy and the
entry of two new InSTIs onto the developed world market within
the next 12–24 months (elvitegravir and dolutegravir) the price of
RAL may be subject to competitive pressures.
Supporting Information
Supporting Material S1 CD4 progression and viral load
assumptions.
(DOC)
Supporting Material S2 Unit costs and ART utilisation
assumptions.
(DOC)
Supporting Material S3 Sensitivity analyses.
(DOC)
Author Contributions
Conceived and designed the experiments: KS JA. Performed the
experiments: KS. Analyzed the data: KS. Wrote the paper: KS.
Acquisition of data: CN RK JA MAB. Interpretation of data: DPW SE
DAC MAB.
References
1. Joint United Nations Programme on AIDS (UNAIDS). (2011) Global HIV/
AIDS Response. Epidemic update and health sector progress towards Universal
Access. Progress Report 2011. Geneva: UNAIDS.
2. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, et al. (2008) Public-
health and individual approaches to antiretroviral therapy: township South
Africa and Switzerland compared. PLoS Med 5: e148.
3. Cahn P (2008) WHO Expert Consultation on ART failure definitions in the
context of the public health approach. 26–27 February 2008 – Montreux,
Switzerland.
4. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, et al.
(2009) The public health approach to identify antiretroviral therapy failure:
high-level nucleoside reverse transcriptase inhibitor resistance among Malawians
failing first-line antiretroviral therapy. AIDS 23: 1127–1134.
5. Manosuthi W, Butler DM, Chantratita W, Sukasem C, Richman DD, et al.
(2010) Patients infected with HIV type 1 subtype CRF01_AE and failing first-
line nevirapine- and efavirenz-based regimens demonstrate considerable cross-
resistance to etravirine. AIDS Res Hum Retroviruses 26: 609–611.
Figure 3. Discounted net monetary benefit. A. Nigerian setting. B. South African setting.
doi:10.1371/journal.pone.0054435.g003
The Cost-Effectiveness of Raltegravir
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e54435
6. Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, et al.
(2003) The safety, tolerability and effectiveness of generic antiretroviral drug
regimens for HIV-infected patients in south India. AIDS 17: 2267–2269.
7. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, et al.
(2010) Second-line treatment in the Malawi antiretroviral programme: high
early mortality, but good outcomes in survivors, despite extensive drug resistance
at baseline. HIV Med 11: 510–518.
8. Lennox JL, DeJesus E, Berger DS, Lazzarin A, Pollard RB, et al. (2010)
Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected
patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
J Acquir Immune Defic Syndr 55: 39–48.
9. Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, et al. (2011) Long-
term treatment with raltegravir or efavirenz combined with tenofovir/
emtricitabine for treatment-naı̈ve human immunodeficiency virus-1 patients:
156-week results from STARTMRK. Clin Infect Dis 53: 807–16.
10. Médecins Sans Frontières (2011) Untangling the web of antiretroviral price
reductions. 14th Edition July 2011. Geneva: Médecins Sans Frontières.
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